Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

Features
Schizophrenia

31 May 05

Schizophrenia can affect anyone, and is one of the greatest causes of lost quality of life worldwide. One-in-100 people will experience this serious mental illness at some time in their lives, though it commonly starts in the late teens to the early 20s in men and early to late 20s in women. Although schizophrenia can have a profound effect, it can be treated effectively in most people. This was not always the case.
CSF Medical Communications

Allergic Rhinitis

31 May 05

Allergic rhinitis is an increasingly prevalent disorder, affecting up to 40% of children and up to 30% of adults in the UK. The disease has traditionally been considered as either seasonal or perennial depending on the allergenic triggers and their presence in the environment. Typically, tree pollen promotes seasonal symptoms between February and April, grass pollens in late May through to early August, whilst weed pollens and mould spores are common in late summer and early autumn.
CSF Medical Communications

Hepatitis A/Typhoid Fever

31 May 05

Although difficult to determine accurately, annual global figures for reported cases of hepatitis A and typhoid are estimated to be in the region of 1.5 million and at least 16 million, respectively. Moreover, typhoid fever accounts for up to 600,000 deaths worldwide each year. The two diseases are often found in partnership and have common routes of transmission, particularly where sanitation is poor.
CSF Medical Communications

Will once-daily Kaletra be enough to see off the threat of Reyataz?

20 May 05

In addition to the traditional clinical needs, such as efficacy and resistance profile, product characteristics such as dosing and side effects can be fundamental in maintaining market share in the maturing antiretroviral market. In response to the launch of two once-daily protease inhibitors (PI), Abbott has reformulated its leading PI drug, Kaletra (lopinavir/ritonavir) in a once-daily dose.
Datamonitor

Have you taken your Medication today? Y or N

18 May 05

With UK MP’s, Committees, Regulatory bodies, Health Services and Companies looking for someone to blame for the dangers of patient non-compliance and drug safety issues it’s time to learn how the simplest technology can deliver the biggest rewards and bring you closer to your patients.
Sarah Eadon

NHS pharmaceutical messaging service

11 May 05

New on-line system for hospital pharmacies makes ordering medicines easier, quicker and, being paperless, virtually error-free.
Mike Wood

Reduce costs & increase efficiency with SMS

11 May 05

Did you know you can generate SMS messages from any software that can send an email or generate an HTTP request such as Outlook, Lotus Notes..?
Mike Wood

Addressing the crisis facing the Clinical Research Staffing market

29 Apr 05

The Healthcare Industry is currently experiencing the effects of a global shortage of qualified and experienced clinical research professionals – and this situation has evolved into the industry’s very own version of ‘Catch 22’. While employers are looking to hire candidates who are already experienced in the practice of clinical research, new Life Science graduates and others wishing to start on a career in the Healthcare Industry are unable to gain such experience without first being hired.
Kieran Engels
European Director CRAcademy

Efficacy and improved tolerability of Hypericum perforatum extract, WS 5570, compared to paroxetine in patients with moderate to severe depression

16 Mar 05

Depression is the most common mental disorder worldwide affecting around 120 million people globally. The depression market is the largest segment of the CNS market with global sales of US$15.5 billion in 2003 although this figure is dropping as generic equivalents of past blockbusters are launched. Although the depression market has matured, key areas of unmet clinical need will have to be addressed in order to drive further growth of the market. These include improvements in the safety/tolerab
LeadDiscovery

Valeant Pharmaceuticals' remofovir mesylate, an improved adefovir prodrug for targeted and tolerable treatment of hepatitis B (HBV) infection

16 Mar 05

According to the WHO, 350-400 million individuals are chronically infected with the hepatitis B virus (HBV). Chronic infection with hepatitis viruses causes cirrhosis and hepatocellular carcinoma, both devastating diseases with few treatments and the demand for effective treatments for hepatitis infection is therefore high. Lamivudine dominates first-line therapy for HBV (see our feature on hepatitis B & C). Gilead's Adefovir prodrug (Hepsera) represent a second line option although nephrotoxici
LeadDiscovery

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.